Status:

COMPLETED

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

Lead Sponsor:

Kala Pharmaceuticals, Inc.

Conditions:

Blepharitis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian g...

Detailed Description

This is a Phase II, multicenter, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the efficacy and safety of KPI-121 ophthalmic suspension versus vehicle in sub...

Eligibility Criteria

Inclusion

  • Have a documented clinical diagnosis of inflammatory meibomian gland disease in both eyes.

Exclusion

  • Known hypersensitivity/contraindication to study product(s) or components.
  • Be currently receiving treatment for glaucoma, have history of or current glaucoma, or an IOP (intraocular pressure) over 21mmHg at Visit 1 (Screening) or Visit 2 (Randomization).
  • Be unwilling to discontinue warm compress therapy, lid expression, or lid massage 14 days prior to Day 1 and for the duration of the study.
  • Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; severe/serious systemic disease or uncontrolled medical condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within the 30 days prior to screening.
  • Have had ocular surgery in the past 90 days or require ocular surgery during the study.
  • In the opinion of Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.

Key Trial Info

Start Date :

July 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2016

Estimated Enrollment :

206 Patients enrolled

Trial Details

Trial ID

NCT02218489

Start Date

July 1 2014

End Date

June 1 2016

Last Update

January 11 2021

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

UAB School of Optometry

Birmingham, Alabama, United States, 35294-0010

2

Sall Research Medical Center

Artesia, California, United States, 90701

3

North Valley Eye Medical Group

Mission Hills, California, United States, 91345

4

Wolstan & Goldberg Eye Associates

Torrance, California, United States, 90505

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease | DecenTrialz